<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
      <JournalTitle>Frontiers in Medical Case Reports</JournalTitle>
      <Volume-Issue>Volume 2; Issue 3</Volume-Issue>
      <Season>(May-Jun, 2021)</Season>
      <ArticleType>Medical Case Reports</ArticleType>
      <ArticleTitle>Peritoneal Carcinomatosis Secondary to Papillary Renal Cell Carcinoma: Case Report</ArticleTitle>
      <Abstract>Renal cell carcinoma accounts for approximately 5% and 3% of all neoplasms diagnosed in men and women respectively, making it the 7th most common neoplasm in the adult population. Nowadays, localized neoplasm can be surgically treated and has a good overall prognosis. When presenting metastatic disease, the most frequent locations of metastasis are the lungs, liver, and bone. Approximately one third of patients with renal stage IV renal cell carcinoma will develop peritoneal metastatic disease but this is a rare presentation as first metastatic localization. We are presenting a 68-year-old patients who underwent partial nephrectomy to treat a localized renal carcinoma who three years after surgery presented peritoneal carcinomatosis as first metastatic location.</Abstract>
      <Keywords>Renal Cell Carcinoma,Peritoneal Carcinomatosis,Biopsy,CT-Scan,PET-CT</Keywords>
        <Abstract>https://jmedicalcasereports.org/ubijournal-v1copy/journals/abstract.php?article_id=9609&amp;title=Peritoneal Carcinomatosis Secondary to Papillary Renal Cell Carcinoma: Case Report</Abstract>
        <References>Cohen HT and Mcgovern FJ. Renal-Cell Carcinoma. N engl J Med 2005; 353: 2477–2490.&#13;
Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, Gruenvald V, Horwich A. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol 2019; 30: 706–720.&#13;
Garcand;iacute;a NR, Tello AMG, Gonzand;aacute;lez LL, Mediero JMG, Cuesta JA, Sand;aacute;nchez AB. Carcinoma renal metastand;aacute;sico a peritoneo. A propand;oacute;sito de un caso. Arch Esp Urol 2006; 59: 919–922.&#13;
Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Lee JL, Hawkins R, Ravaud A, Alekseev B, Staehler M, Uemura M, De Giorgi U, Mellado B, Porta C, Melichar B, Gurney H, Bedke J, Choueiri TK, Parnis F, Khaz MR. IMmotion151 Study Group. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): A multicentre, open-label, phase 3, randomised controlled trial. Lancet 2019; 393: 2404-2415.&#13;
Sidana A, Kadakia M, Friend JC, Krane LS, Su D, Merino MJ, Srinivasan R. Determinants and prognostic implications of malignant ascites in metastatic papillary renal cancer. Urol Oncol Semin Orig Investig 2017; 35: 114.e9-114.e14.&#13;
Stavropoulos NJ, Deliveliotis C, Kouroupakis D, Demonakou M, Kastriotis J, Dimopoulos C. Renal cell carcinoma presenting as a large abdominal mass with an extensive peritoneal metastasis. Urol Int 1995; 54: 169-170.&#13;
Zamir N, Akhtar J, Ahmed S. Omental cake: a radiological diagnostic sign. APSP J Case Rep 2011; 2: 27.</References>